A challenge for clinical laboratories: Detection of antifungal resistance in Candida species causing vulvovaginal candidiasis

Laboratory Medicine

Volumn 42, Issue 2, 2011, Pages 87-93

  Dota, Kelen F D ^a   Freitas, Alessandra R ^a   Consolaro, Marcia E L ^a   Svidzinski, Terezinha Inez Estivalet ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Broth microdilution; Correlation; Disk diffusion; Laboratory test; Vaginal yeasts; Vulvovaginal candidiasis

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CLINICAL LABORATORY; CONTROLLED STUDY; DISK DIFFUSION; IN VITRO STUDY; NONHUMAN; STANDARDIZATION; VAGINA CANDIDIASIS; VAGINA FLORA;

CANDIDA;

EID: 79251483806     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMDFCA8YEZ0MQULA     Document Type: Article

References (37)

1. Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol. 1993;36:153-165.
2. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369:1961-1971.
3. Boato HF, Moraes MS, Machado AP, et al. Correlação entre os resultados laboratoriais e os sinais e sintomas clínicos das pacientes com candidíase vulvovaginal e relevância dos parceiros sexuais na manutenção da infecção em São Paulo, Brasil. Rev Bras Ginecol Obstet. 2007;29:80-84.
4. Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am. 2008;22:637-652.
5. Ozcan SK, Budak F, Yucesoy G, et al. Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women. APMIS. 2006;114:139-145. (Pubitemid 43356925)
6. Rivera-Sánchez R, Flores-Paz R, Arriaga-Alba M. Identificación de especies de Candida causantes de vaginitis en la población mexicana. Enferm Infecc Microbiol Clin. 2006;24:634-636. (Pubitemid 46141733)
7. Consolaro MEL, Albertoni TA, Yoshida CS, et al. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringá, Paraná, Brazil. Rev Iberoam Micol. 2004;21:202-205.
8. Ferrazza MHSH, Maluf MLF, Consolaro MEL, et al. Characterization of yeasts isolated from the vagina and their association with vulvovaginal candidíasis in two cities of the South of Brazil. Rev Bras Ginecol Obstet. 2005;27:58-63.
9. Sobel JD. Vulvovaginitis due to Candida glabrata: An emerging problem. Mycoses. 1998;41:18-22.
10. Watson C, Calabretto H. Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Aust N Z J Obstet Gynaecol. 2007;47:262-272.
11. Ribeiro MA, Dietze R, Paula CR, et al. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia. 2001;151:5-10. (Pubitemid 32682603)
12. Galle LC, Mendes-Gianini MJS. Prevalência e susceptibilidade de leveduras vaginais. J Bras Patol Med Lab. 2004;40:229-236.
13. Asticcioli S, Sacco L, Daturi R, et al. Trends in frequency and in vitro antifungal susceptibility patterns of Candida isolates from women attending the STD outpatients clinic of a tertiary care hospital in Northern Italy during the years 2002-2007. New Microbiol. 2009;32:199-204.
14. Muriel MA, Vizcaíno MJ, Bilbao R, et al. Identificación de levaduras y sensibilidad in vitro a diversos antifúngicos. Enferm Infecc Microbiol Clin. 2000;18:120-124. (Pubitemid 30488956)
15. Fan SR, Liu XP. Nonalbicans Candida species and antifungal susceptibility. Int J Gynaecol Obstet. 2007;98:158-159. (Pubitemid 47042739)
16. Richter SS, Galask RP, Messer SA, et al. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43:2155-2162.
17. Saporiti AM, Gómez SL, Galeano M, et al. Candidiasis vaginal: Etiologia y perfil de sensibilidade a agentes antifúngicos de uso clínico. Rev Argent Microbiol. 2001;33:217-222.
18. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. M27-A. Wayne, PA: NCCLS; 1997.
19. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts - Second Edition; Approved Standard. M27-A3. Wayne, PA: CLSI; 2008.
20. CLSI. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline. M44-A. Wayne, PA: CLSI; 2004.
21. Negri M, Henriques M, Svidzinski TI, et al. Correlation between Etest, disk diffusion, and microdilution methods for antifungal susceptibility testing of Candida species from infection and colonization. J Clin Lab Anal. 2009;23:324-330.
22. Pfaller MA, Boyken L, Messer SA, et al. Stability of Mueller-Hinton agar supplemented with glucose and methylene blue for disk diffusion testing of fluconazole and voriconazole. J Clin Microbiol. 2004;42:1288-1289. (Pubitemid 38332869)
23. Barry AL, Pfaller MA, Rennie RP, et al. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother. 2002;46:1781-1784.
24. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, et al. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother. 2003;47:1647-1651.
25. rd ed. Washington, DC: ASM Press; 2005.
26. Shinobu CS, Ogatta SFY, Bizerra F, et al. Lack of association between genotypes and virulence factors in Candida albicans strains isolated from vaginal secretion. Braz J Microbiol. 2007;38:467-471.
27. Dalben-Dota KF, Faria MG, Bruschi ML, et al. Antifungal activity of propolis extract against yeasts isolated from vaginal exudates. J Altern Complement Med. 2010;16:285-290.
28. Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol. 2003;41:1440-1446.
29. Dota KFD, Shinobu CS, Patussi EV, et al. Susceptibility to vaginal yeast in most used antifungal in Maringá, Paraná, Brazil. Acta Bioquim Clín Latinoam. 2008;42:561-566.
30. Bauters TG, Dhont MA, Temmerman MI, et al. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol. 2002;187:569-574.
31. Ferrer J. Vaginal candidosis: Epidemiological and etiological factors. Int J Gynaecol Obstet. 2000;71:S21-S27.
32. McCaig LF, McNeil MM. Trends in prescribing for vulvovaginal candidiasis in the United States. Pharmacoepidemiol Drug Saf. 2005;14:113-120.
33. Fan SR, Liu XP. In vitro miconazole susceptibility and clinical outcome in vulvovaginal candidiasis. Int J Gynaecol Obstet. 2007;97:207-208.
34. Donders G, Bellen G, Byttebier G, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. 2008;199:613.e1-613.e9.
35. Mock M, Monod M, Baudraz-Rosselet F, et al. Tinea capitis dermathophytes: Susceptibility to antifungal drugs tested in vitro and in vivo. Dermatology. 1998;197:361-367.
36. Fan SR, Liu XP, Li JW. Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res. 2008;34:561-566.
37. Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother. 2003;47:34-38. (Pubitemid 36070338)